AHL Partners LLP grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,227 shares of the biopharmaceutical company’s stock after acquiring an additional 11,337 shares during the period. AHL Partners LLP’s holdings in Gilead Sciences were worth $4,970,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also bought and sold shares of the business. Penserra Capital Management LLC grew its stake in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares in the last quarter. American Beacon Advisors Inc. acquired a new position in shares of Gilead Sciences during the first quarter worth $143,000. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares in the last quarter. Capstone Investment Advisors Netherlands B.V. acquired a new position in shares of Gilead Sciences during the second quarter worth $172,000. Finally, Sterling Investment Advisors Ltd. acquired a new position in shares of Gilead Sciences during the second quarter worth $184,000. Institutional investors and hedge funds own 76.23% of the company’s stock.
In other news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the sale, the executive vice president now directly owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock valued at $37,404,139 over the last ninety days. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the prior year, the company earned $2.75 earnings per share. The business’s revenue was down 13.2% compared to the same quarter last year. equities research analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.84%. Gilead Sciences’s payout ratio is 23.69%.
A number of equities analysts recently commented on the stock. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $73.67 to $94.00 in a research note on Thursday, November 30th. Argus downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and boosted their target price for the stock from $73.25 to $73.77 in a research note on Monday, November 13th. Mizuho boosted their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. BMO Capital Markets lowered their target price on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Finally, J P Morgan Chase & Co set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $85.22.
TRADEMARK VIOLATION NOTICE: “AHL Partners LLP Boosts Holdings in Gilead Sciences, Inc. (GILD)” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/12/07/ahl-partners-llp-boosts-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.